The lab is dedicated to improving the outcomes of people who suffer from gut disorders, including Inflammatory Bowel Diseases (IBD) such as Crohn’s Disease and Ulcerative Colitis.
The clinical research programs are undertaken in parallel with scientific research and aims to discover the cause of these conditions, improve management strategies and develop new treatments so that we can improve the lives of patients living with these incurable conditions. Our group collaborates with local, national and international experts in healthcare, science and industry.
We combine expert state-of-the-art scientific research programs integrated with clinical studies and trials. Our track record in changing outcomes, advancing scientific understanding and treatment of inflammatory bowel disease is outstanding and recognised nationally and overseas. Our research is high impact, presented internationally, and published in the world’s top journals.
Recent successful programs include world-first trials of medication to treat bowel damage from Crohn’s disease, and a clinical trial to determine how best to treat Crohn’s disease after a bowel resection to prevent disease recurring and to reduce the need for further surgery. We are currently running the first ever comprehensive randomised trial of faecal microbiota transplantation (FMT) to treat active Crohn’s disease. We also conduct dietary studies to develop diet strategies to help treat inflammation in patients with inflammatory bowel disease.
We have a program of laboratory projects derived from past, current and future clinical studies to address the contribution of the Gut Microbiome to these disabling, chronic conditions and to help develop new treatment targets and therapeutics.
AGIRF